Immunglobulins and Septicemia

Öz

 Due to placental type of ruminants and equines, immunoglobulins cannot pass through from mother to newborn and immunity of these animals are provided with colostrum. Failure of passive transfer occurs in ani-mals that cannot receive colostrum in first 48 hours and this situation causes catching an infection easily in neo-nate. The most common diseases that occur due to failure of passive transfer are septicemic diseases. In order to prevent septicemic diseases, antimicrobial therapy and supportive therapy are used today. As a result of scientific research in recent years, it was reported that immunoglobulins are used in support therapy of septicemic disease. Our purpose in this review are to evaluate the published studies on septicemia and immunoglobulins in the light of present scientific knowledge and in accordance with these evaluations, inform scientists, private veterinarians and breeders about the use of immunoglobulins in veterinary. 

Anahtar Kelimeler

• Immunoglobulin,Septicemia,Sepsis,Neonatal animal,Treatment

İmmünglobulinler ve Septisemi

Öz

 İmmünglobulinler geviş getiren ve tek tırnaklı hayvanlardaki plasenta tipi nedeniyle anneden yavruya geçememekte ve bu hayvanların bağışıklığı doğumu takiben alınan kolostrum sütü ile sağlanmaktadır. İlk 48 saat içinde yeterli miktarda kolostrum alamamış hayvanlarda pasif transfer yetmezliği sendromunun ortaya çıkmakta ve bu durum yavruların kolayca enfeksiyona yakalanmasına yol açmaktadır. Pasif transfer yetmezliği sebebiyle ortaya çıkan hastalıkların başında septisemik hastalıklar gelmektedir. Septisemik hastalıkların önüne geçmek için günümüzde antimikrobiyal tedavi ve destek tedavileri uygulanmaktadır. Son yıllardaki bilimsel araştırmalar neticesinde immünglobulinlerin septisemik hastalıklarda uygulanan destek tedavisinde kullanıldığı bildirilmiştir. Bu derlemedeki temel amacımız güncel bilimsel bilgiler ışığında immünglobulinler ve septisemi konularında dünya çapında yapılmış bulunan çalışmaları değerlendirmek ve bu değerlendirmeler doğrultusunda immünglobu-linlerin veteriner hekimlikteki kullanımı hakkında bilim insanlarını, sahadaki veteriner hekimleri ve yetiştiricileri bilgilendirmektir. 

Anahtar Kelimeler

• İmmünglobulin,Septisemi,Sepsis,Yeni doğan hayvan,Tedavi

Kaynakça

1. Akşit, F., Akgün, Y., Kiraz, N., 1996. Mikrobiyoloji. Anadolu Üniversitesi Yayınları, Eskişehir.
2. Alanoğlu, G., 2007. Özgün olmayan immünglobulin kullanımı. Türk Hematoloji Derneği Hematolojide Destek Tedaviler Kursu, 15-17 Kasım, Erzurum. http://www.thd.org.tr/thdData/userfiles/file/HEM_DES_2007_1.pdf. Erişim Tarihi: 10.04.2013.
3. Altıntaş, A., Kantarcı, O., Siva, A., 1996. Otoimmun nörolojik hastalıklarda tedavi stratejileri. Türk Nöroloji Dergisi, 2 (3-4), 70-78.
4. Anonim, 2005. Kuduz korunma ve kontrol yönergesi. http://www.saglik.gov.tr/TR/dosya/1-75996/h/kuduz-korunma-ve-kontrol-yonergesi.doc. Erişim Tarihi: 10.04.2013.
5. Anonim, 2007. İdiyopatik trombositopenik purpura. Uludağ Üniversitesi Sağlık Kuruluşları ÇSH Anabilim Dalı. http://sakur.uludag.edu.tr/dosya/FR-HYE-04-416-02.pdf. Erişim Tarihi: 10.04.2013).
6. Arısoy, E.S., 2010. Yenidoğan sepsisi: Tanı ve tedavi yaklaşımları. Ankem Dergisi, 24 (2), 168-175.
7. Aydoğdu, B., Yurtçu, M., Akbulut, S., Gürbilek, M., Toy, H., Günel, E., 2008. Deneysel nekrotizan enterokolit modelinde ağız yolu ile verilen immünglobülin A’nın etkisi. Çocuk Cerrahisi Dergisi, 22 (1), 8-14.
8. Balan, P., Han, K.S., Rutherfurd-Markwick, K., Singh, H., Moughan, P.J., 2010. Immunomodulatory effects of ovine serum immunoglobulin in the growing rat. Animal, 4(10), 1702-1708.

9. Basoglu, A., Camkerten, I., Serving, M., 1999. Serum immunoglobulin concentrations in diarrheic calves and their measurement single radial immunodiffusion. Israel Journal of Veterinary Medicine, 54 (1), 9-10.
10. Behre, G., Schedel, I., Nentwig, B., Wörmann, B., Essink, M., Hiddemann, W., 1992. Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins. Antimicrobial Agents and Chemotherapy, 36 (10), 2139-2146.
11. Berlot, G., Bacer, B., Piva, M., Lucangelo, U., Viviani, M., 2007. Immunoglobulins in sepsis. Advances In Sepsis, 6 (2), 41-46.
12. Bianco, D., Armstrong, J., Washabau, R., 2007. Threatment of severe immune-mediated thrombocytopenia with human IV immunoglobulin in 5 dogs. Journal of Veterinary Internal Medicine, 21 (4), 694-699.
13. Boros, P., Gondolesi, G., Bromberg, J.S., 2005. High dose intravenous immunoglobulin treatment: mechanisms of action. Liver Transplantation, 11 (12), 1469-1480.
14. Breedveld, F., 2000. Therapeutic monoclonal antibodies. Lancet, 355, 735-740.
15. Bruton, O.C., 1952. Agammaglobulinemia. Pediatrics, 9 (6), 722-728.
16. Byrne, K.P., Giger, U., 2002. Use of human immunoglobulin for threatment of severe erythema multiforme in a cat. Journal of the American Veterinary Medical Association, 220 (2), 197-201.
17. Camcıoğlu, Y., Aytaç, E., 2007. Sepsisin immünopatogenezisi. Türk Yoğun Bakım Dergisi, 5, 81-85.
18. Camcıoğlu, Y., 2009. İmmunglobulin tedavisi. Journal of Pediatric Infection, 3, 69-74.
19. Cohn, E.J., Luetscher, J.A., Oncley, J.L., Armstrong Jr, S.H., Davis, B.D., 1940. Preparation and properties of serum and plasma proteins. III. Size and charge of proteins separating upon equilibration across membranes with ethanol-water mixtures of controlled pH, ionic strength and temperature. Journal of the American Chemical Society, 62 (12), 3396-3400.
20. Craft, J.M., Watterson, D.M., Van Eldik, L.J., (2005). Neuroinflammation: a potential therapeutic target. Expert Opinion on Therapeutic Targets, 9, 887-900.
21. Çakıroğlu, D., Meral, Y., Pekmezci, D., Onuk, E.E., Gökalp, G., 2010. Yeni doğan buzağılarda çeşitli hematolojik ve biyokimyasal parametreler ile kolostral immun globulinler arasındaki ilişkinin belirlenmesi. Fırat Üniversitesi Sağlık Bilimleri Veteriner Dergisi, 24 (1), 43-46.
22. Çitil, M., Karapehlivan, M., Güneş, V., Atakişi, E., Uzlu, E., 2004. Septisemi şüpheli buzağılarda serum sialik asit ve bazı biyokimyasal parametre düzeyleri. Kafkas Üniversitesi Veteriner Fakültesi Dergisi, 10 (1), 19-22.
23. Deymeer, F., 2005. Myasthenia Gravis'te tedavi. Türkiye Klinikleri Dahili Tıp Bilimleri Dergisi, 1 (22), 38-43.
24. Diker, K.S., (2005). İmmunoloji. Medisan Yayınları, Ankara.
25. Esen, F., Senturk, E., Ozcan, P.E., Ahishali, B., Arican, N., Orhan, N., Ekizoğlu, O., Ustek, D., Kucuk, M., Kaya, M., 2012. Intravenous immunoglobulins prevent the breakdown of the blood-brain barrier in experimentally induced sepsis. Critical Care Medicine, 40 (4), 1214-1220.
26. Francisco, S.A., Quigley III, J.D., 1993. Serum immunoglobulin concentrations after feeding maternal colostrum or maternal colostrum plus colostral supplement to dairy calves. American Journal of Veterinary Research, 54 (7), 1051-1054.
27. Gasque, P., Fontaine, M., Morgan, B.P., 1995. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. The Journal of Immunology, 154 (9), 4726-4733.
28. Gelfand, E.W., 2012. Intravenous immune globulin in autoimmune and inflammatory diseases. New England Journal of Medicine, 367 (21), 2015-2025.
29. Gomez, S.M., Morris, D.O., Rosenbaum, M.R, Goldschmidt, M.H., 2004. Outcome and complications associated with treatment of pemphigus foliaceus in dogs: 43 cases (1994-2000). Journal of the American Veterinary Medical Association, 224 (8), 1312-1316.
30. Hammer, C., Tyler, H., Roth, J.A., Quigley III, J.D., 2004. Characterization of reactions to intravenous immunoglobulin in neonatal calves. Animal Industry Report, 650 (1), 66.
31. Hamrock, D.J., 2006. Adverse events associated with intravenous immunoglobulin therapy. International Immunopharmacology, 6 (4), 535-542.
32. Imbach, P., Barandun, S., d’Apuzzo, V., Baumgartner, C., Hirt, A., Morell, A., Rossi, E., Schoni, M., Vest, M., Wagner, H.P., 1981. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet, 317 (8232), 1228-1231.
33. Jacob, A., Hensley, L.K., Safratowich, B.D., Quigg, R.J., Alexander, J.J., 2007. The role of complement cascade in endotoxin-induced septic encephalopathy. Laboratory Investigation, 87 (12), 1186-1194.
34. Jenson, H.B., Pollock, B.H., 1998. The role of intravenous immunoglobulin for the prevention and treatment of neonatal sepsis. Seminars in Perinatology, 22 (1), 50-63.
35. İnce, E., 2011. Sepsis ve septik şok tedavisi. Journal of Pediatric Infection, 5 (1), 106-118.
36. Karadal, A.E., 2009. SIRS ve sepsis hastalarında deksmedetomidin ve propofolün immün sistem üzerine etkileri. Uzmanlık Tezi, Çukurova Üniversitesi Tıp Fakültesi Anestezi ve Reanimasyon Anabilim Dalı, Adana.
37. Kav, K., Erganiş, O., 2008. Balıklarda bağışıklık sistemi. Eurasian Journal of Veterinary Sciences, 24 (1), 97-106.
38. Keleş, İ., Ceylan, C., Erbaş, O., 2012. Çocukta sıra dışı penil travma: Köpek ısırması olgusu. Sakarya Medical Journal, 2 (2), 99-101.
39. Kellerman, D.L., Bruyette, D.S., 1997. Intravenous human immunoglobulin for the treatment of immune-mediated hemolytic anemia in 13 dogs. Journal of Veterinary Internal Medicine, 11 (6), 327-332.
40. Kılıç, S.Ş., (2003). İmmun yetmezlikli hastalarda intravenöz immünglobulin tedavisi. Güncel Pediatri, 1, 92-95.
41. Kırış, S., 1990. İntravenöz immünglobulin preparatlarının yapısal ve işlevsel özellikleri. Ankem Dergisi, 4 (3), 390-400.
42. Koffman, B.M., Dalakas, M.C., 1997. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: Assessments based on controlled treatment trials in patients with neurological diseases. Muscle & Nevre, 20 (9), 1102-1107.
43. Kol, A., 2008. Human intravenous immunoglobulin (IVIG) therapy in veterinary medicine - A review. Israel Journal of Veterinary Medicine, 63 (1), 23-27.
44. Kreymann KG, de Heer G, Nierhaus A, Kluge S (2007). Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Critical Care Medicine, 35 (12), 2677-2685.
45. Kulkarni, A.P., Kellaway, L.A., Lahiri, D.K., Kotwal, G.J., 2004. Neuroprotection from complement-mediated inflammatory damage. Annals of the New York Academy of Sciences, 1035 (1), 147-164. Lemieux, R., Bazin, R., Néron, S., 2005. Therapeutic intravenous immunoglobulins. Molecul r Immunology, 42 (7), 839-848.
46. Losonsky, G.A., Johnson, J.P., Winkelstein, J.A., Yolken, R.H., 1985. Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. A pharmacokinetic and functional analysis. Journal of Clinical Investigation, 76 (6), 2362-2367.
47. Mueller, R.S., Krebs, I., Power, H.T., Fieseler, K.V., 2006. Pemphigus foliaceus in 91 dogs. Journal of the American Animal Hospital Association, 42 (3), 189-196.
48. Norby-Teglund, A., Haque, K.N., Hammarström, L. 2006. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relat
49. Nutall, T.J., Malham, T., 2004. Successful intravenous human immunoglobulin threatment of drug-induced Stevens-Johnson syndrome in a dog. Journal of Small Animal Practice, 45 (7), 357-361.
50. Oesser, S., Schulze, C., Seifert, J., 1999. Protective capacity of a IgM/IgA-enriched polyclonal immunoglobulin-G preparation in endotoxemia. Research in Experimental Medicine, 198 (6), 325-339.
51. Oflazoğlu, B., Öztürk, F., Açık, H.K., Öncel, Ç., Anadol, Ü., Forta, H., 2006. Nörolojik hastalıklarda IV immünglobulin tedavisinin yan etkileri. Türk Nöroloji Dergisi, 12 (1), 21-24.
52. Öneş, Ü., 1990. İntravenöz immünglobulinlerin klinik uygulamaları. Ankem Dergisi, 4 (3), 401-406.
53. Rahilly, K.J., Keating, J.H., O’Toole, T.E., 2006. The use of intravenous human immunoglubulin in threatment of severe pempohigus foliaceus in a dog. Journal of Veterinary Internal Medicine, 20 (6), 1483-1486.
54. Schedel, I., Dreichhausen, U., 1995. The therapy of gram-negative septicotoxic diseases with pentaglobin, an immunoglobulin with an elevated IgM content (a prospective, randomized clinical study). Anesteziologiia i Reanimatologiia, 199, 4-9.
55. Schwartz, S.A., 1990. Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders. Journal of Clinical Immunology, 10 (2), 81-89.
56. Schwartz, S.A., 2000. Intravenous immunoglobulin treatment of immunodeficiency disorders. Pediatric Clinics of North America, 47 (6), 1355-1369.
57. Scott-Moncrieff, J.C., Snyder, P.W., Reagan, W.J., Glickman, L.T., 1997. Intravenous administration of human immune globulin in dogs with immune-mediated hemolytic anemia. Journal of the American Veterinary Medical Association, 210 (11), 1623-1627.
58. Şentürk, E., Esen, F., 2012. Sepsiste immunoglobülin tedavisi ile kompleman inhibisyonu ve nöroproteksiyon. Türk Anesteziyoloji ve Reanimasyon Derneği Dergisi, 40 (4), 184-192.
59. Tel. N., Öner, Ü., Paşaoğlu, Ö., 1991. Patoloji. Anadolu Üniversitesi Yayınları, Eskişehir.
60. Thampakkul, S., Ballow, M., 2001. Replacement intravenous immune serum globulin therapy in patients with antibody immune deficiency. Immunology and Allergy Clinics of North America, 21 (1), 165-184.
61. Toprak, D., Soysal, A., Türel, Ö., Bakır, M., 2007. Rotavirüs ishalinde oral immunoglobulin tedavisi: İki olgu sunumu. Çocuk Enfeksiyon Dergisi, 1, 115-117.
62. Trotman, T.K., Philips, H., Fordyce, H., King, L.G., Morris, D.O., Giger, U., 2006. Threatment of severe adverse cutaneous drug reactions with human intravenous immunoglobulin in two dogs. Journal of the American Animal Hospital Association, 42 (4), 312-320.
63. Tuncer, E., Kılıç, Ş., 2006. Yenidoğanın immün sistemi. Güncel Pediatri, 3, 92-95.
64. van Engelen, B.G., Miller, D.J., Pavelko, K.D., Hommes, O.R., Rodrigues, M., 1994. Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple screlosis. Journal of Neurology, Neurosurgery, and Psychiatry, 57, 65-68.
65. von Behring, E., Kitasato, S., 1890. Ueber das zustandekommen der diphtherie-immunitgt und der tetanus-immunitzt bei thieren. Deutscbe Medizhiscbe Wocbenschift, 16, 1113-1114.
66. Werdan, K., 2001. Pathophysiology of septic shock and multiple organ dysfunction syndrome and various therapeutic approaches with special emphasis on immunoglobulins. Therapeutic Apheresis and Dialysis, 5 (2), 115-122.
67. Whelan, M.F., O'Toole, T.E., Chan, D.L., Rozanski, E.A., DeLaforcade, A.M., Crawford, S.L., Cotter, S.M., 2009. Use of human immunoglobulin in addition to glucocorticoids for the initial treatment of dogs with immune-mediated hemolytic anemia. Journal of Veterinary Emergency and Critical Care, 19 (2), 158-164.
68. Wolach, B., 1997. Neonatal sepsis: Pathogenesis and supportive therapy. Seminars in Perinatology, 21 (1), 28-38.
69. Yıldızdaş, D., Yapıcıoğlu, H., Tümgör, G., Erbey, F., 2005. Çocuk yoğun bakım ünitesi'nde sepsis nedeni ile izlenen hastalarda poliklonal intravenöz immünglobülin tedavisi mortaliteyi azaltıyor mu. Çocuk Sağlığı ve Hastalıkları Dergisi, 48, 136-141.
70. Ziegler, E.J., McCutchan, J.A., Fierer, J., Glauser, M.P., Sadoff, J.C., Douglas, H., Braude, A.I., 1982. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. New England Journal of Medicine, 307 (20), 1225-1230.